The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease Management of comorbidities in kidney disease in the 21st century: Anemia and bone disease

The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney diseaseBackgroundProvision of adequate iron to support erythropoiesis in patients with chronic kidney disease (CKD) is time consuming and may present adherence problems for patients in the outpatient setting. We studied an accelerated regimen of high-dose intravenous iron sucrose therapy in a cohort of iron-deficient, anemic CKD patients.MethodsIntravenous iron sucrose 500mg was infused over three hours on two consecutive days in 107 CKD patients (glomerular filtration rate, 32.3 ± 19.6mL/min/1.73m2, baseline hemoglobin 10.2 ± 1.7g/dL). Iron indices (transferrin saturation, ferritin) were measured at baseline and at two and seven days after completion of the iron regimen. Blood pressures were monitored immediately prior to, and hourly throughout the iron sucrose infusions.ResultsTransferrin saturation and serum ferritin increased from 18.5 ± 8.5% and 177 ± 123.8ng/mL at baseline to 40.2 ± 22.3% and 811 ± 294.1ng/mL in 102 evaluated patients (P < 0.015). In 55 patients with additional measurements at 7days post-dosing, the transferrin saturation and ferritin had fallen to 26.3 ± 10.6% and 691 ± 261.8ng/mL (P < 0.015 compared to two days' post-dose). Blood pressure rose slightly, but not significantly, throughout the infusions, and altering the infusion rate was not necessary. Two patients had seven adverse events that were considered related to iron sucrose.ConclusionAn accelerated regimen of high-dose intravenous iron sucrose therapy in CKD patients is safe and effective in restoring iron stores, and may potentially save time and improve patient adherence